Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial - Iain B. McInnes; Philip J. Mease; Bruce Kirkham; Arthur Kavanaugh; Christopher T. Ritchlin; Proton Rahman; Désirée van der Heijde; R. Landewé; Philip G. Conaghan; Alice B. Gottlieb; Hanno B. Richards; Luminita Pricop; et al. (2015)